EUVIMEDEUVIMED entdecken
Crossref

Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT

Yuan Gao, Zijian Fu, Xiaojuan Zhu, Hongfeng Li, Lei Yin, Caixia Wu, Jinzhi Chen, Yulong Chen, Li Liang, Jingming Ye iD, Ling Xu iD, Meng Liu iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07306-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Yuan Gao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Tumor Microenvironment, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, National High-Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The intricateness of tumor immune microenvironment types (TIMTs) complicates identifying responders to immune checkpoint inhibitors (ICIs). Our purpose was to explore the metabolic characteristics of TIMTs in breast cancer using 18F-fluorodeoxyglucose (FDG) PET/CT and to establish radiomics-based predictive models for TIMTs. METHODS: Consecutive 207 breast cancer patients (211 primary lesions), who underwent 18F-FDG PET/CT examination from Sep 2022 to Aug 2024 in our hospital, were retrospectively reviewed. The programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) were evaluated for TIMTs: TMIT-I (PD-L1-, TILs-), TMIT-II (PD-L1+, TILs+), TMIT-III (PD-L1-, TILs+), and TMIT-IV (PD-L1+, TILs-). The relationship between metabolic parameters (such as maximum standardized uptake value (SUVmax) and tumor-to-liver SUV ratio (TLR)) and TIMTs was analyzed. Then composite predictive models based on radiomics were further developed. RESULTS: TIMT-II represented the highest proportion in HER2+ (14/22, 64%) and triple-negative (17/27, 63%) breast cancer. Most metabolic parameters (such as SUVmax and TLR) exhibited significant differences in TIMT-II vs. -I or TIMT-II vs. -III (P < 0.05). TLR (P = 0.03; OR: 1.1) and Nottingham grade (P = 0.006; OR: 3.1) were independent impact factors of TIMT-II. We further developed a composite model that integrated radiomics, metabolic parameter, and clinicopathological data, which demonstrated promising predictive efficacy for TIMT-II (AUC testing set = 0.86). CONCLUSION: Metabolic differences existed among different TIMTs, with TIMT-II exhibiting markedly elevated metabolic characteristics. The composite model based on radiomics demonstrated high predictive efficacy for TIMT-II and has the potential to screen ICIs responders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Tumor MicroenvironmentBreast NeoplasmsImage Processing, Computer-AssistedHumansFemaleMiddle AgedRetrospective StudiesAgedAdultLymphocytes, Tumor-InfiltratingAged, 80 and overRadiomics

Stichwörter der Autor:innen

18F-FDG PET/CTBreast cancerImmune checkpoint inhibitors (ICIs)RadiomicsTumor immune microenvironment types (TIMTs)

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
  • Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
  • Department of Pathology, Peking University First Hospital, Beijing, China.
  • Institute of Medical Technology, Peking University Health Science Center, Beijing, China.
  • Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China. md_ye@sina.com.
  • Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China. Ling.xu@pkufh.com.

ORCID-Profile: Jingming Ye, Ling Xu, Meng Liu

Förderung

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • National High-Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital)
  • Youth Clinical Research Special Fund Project of Peking University First Hospital

Zitieren

APA

Gao, Y., Fu, Z., Zhu, X., Li, H., Yin, L., Wu, C., Chen, J., Chen, Y., Liang, L., Ye, J., Xu, L., & Liu, M. (2025). Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07306-y

Vancouver

Gao Y, Fu Z, Zhu X, Li H, Yin L, Wu C, et al. Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07306-y

BibTeX
@article{Gao2025,
  author = {Gao, Yuan and Fu, Zijian and Zhu, Xiaojuan and Li, Hongfeng and Yin, Lei and Wu, Caixia and Chen, Jinzhi and Chen, Yulong and Liang, Li and Ye, Jingming and Xu, Ling and Liu, Meng},
  title = {Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07306-y}
}
Kostenlos starten →